• Investor Type  Corporate Venture Capital, Venture Capital
  • Investment Stage  Early Stage Venture, Late Stage Venture, Post-Ipo, Secondary Market, Seed
  • Number of Exits 
  • Company Type For Profit
  • Contact Email klydon@sosei.com
  • Phone Number 877 280 2296

Novartis Venture Fund's primary focus is on the development of novel therapeutics and platforms. They balance the therapeutic focus with investments in medical devices, diagnostics, or drug delivery systems. In their investments, they look for unmet needs and clinical impact, novel proprietary science, an understanding of mechanism, management

and board experience, and capital efficiency in the program.

Novartis Venture Fund prefers to have their initial investment at the early stage to build the company and follow with additional investment in pace with the company's progress. Their approach involves larger focused investments, with anticipation of total investments up to USD 30 to 50 million per company over its life, but it can be as little as 100,000 USD to get started. They plan to increase their activities to lead or co-lead deals further and remain open to participating in larger syndicates.

Lists Featuring This Company

Venture Capital Investors with Investments in Southeast Asia
2,759 Number of Organizations • $32.5B Total Funding Amount • 1,022 Number of Investors
Secondary Market Investors with Investments in Silicon Valley
139 Number of Organizations • $16.9B Total Funding Amount • 26 Number of Investors
Investors Active in Bern, Bern
61 Number of Organizations • $113.2M Total Funding Amount • 19 Number of Investors
Europe, Middle East, and Africa (EMEA) Secondary Market Investors
166 Number of Organizations • $17B Total Funding Amount • 45 Number of Investors